AptaBio receives Phase 2 topline data for APX — 115 in contrast — induced acute kidney injury trial
AptaBio received topline Phase 2 data for Isuzinaxib (APX-115) in contrast-induced acute kidney injury on Oct. 14, 2026. The study met its primary safety objective, with no clinically meaningful safety signals versus placebo in overall participants. Safety findings also held in the higher-risk subgroup with impaired kidney function, supporting continued development. Some efficacy findings are slated for presentation at ASN 2026 in a late-breaking oral session. A final clinical study report is expected in the first half of 2027. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AptaBio Therapeutics Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261014900633), on October 14, 2026, and is solely responsible for the information contained therein. (C)
AptaBio received topline Phase 2 data for Isuzinaxib (APX-115) in contrast-induced acute kidney injury on Oct. 14, 2026. The study met its primary safety objective, with no clinically meaningful safety signals versus placebo in overall participants. Safety findings also held in the higher-risk subgroup with impaired kidney function, supporting continued development.
Some efficacy findings are slated for presentation at ASN 2026 in a late-breaking oral session. A final clinical study report is expected in the first half of 2027. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice.
AptaBio Therapeutics Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261014900633), on October 14, 2026, and is solely responsible for the information contained therein. (C)